Brokerages Expect Innophos Holdings, Inc. (IPHS) to Post $0.59 Earnings Per Share

Innophos Holdings, Inc. (NASDAQ:IPHS) has earned an average broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation. Innophos’ rating score has declined by 50% in the last three months as a result of a number of analysts’ upgrades and downgrades.

Zacks has also assigned Innophos an industry rank of 42 out of 255 based on the ratings given to related companies.

A number of equities research analysts recently weighed in on the company. BidaskClub upgraded Innophos from a “hold” rating to a “buy” rating in a research note on Wednesday, June 6th. TheStreet upgraded Innophos from a “c+” rating to a “b” rating in a research note on Wednesday, May 30th. Finally, Zacks Investment Research upgraded Innophos from a “hold” rating to a “buy” rating and set a $51.00 price target on the stock in a research note on Wednesday, May 9th.

Hedge funds and other institutional investors have recently modified their holdings of the business. Ramsey Quantitative Systems acquired a new position in Innophos in the 4th quarter valued at $134,000. Vident Investment Advisory LLC acquired a new position in Innophos in the 4th quarter valued at $201,000. Alps Advisors Inc. acquired a new position in Innophos in the 4th quarter valued at $213,000. GW&K Investment Management LLC acquired a new position in Innophos in the 1st quarter valued at $222,000. Finally, Verition Fund Management LLC acquired a new position in Innophos in the 1st quarter valued at $237,000. 95.27% of the stock is currently owned by hedge funds and other institutional investors.

IPHS traded up $0.18 during trading hours on Monday, reaching $48.64. The company’s stock had a trading volume of 520 shares, compared to its average volume of 126,213. Innophos has a 52 week low of $38.66 and a 52 week high of $51.34. The company has a current ratio of 3.22, a quick ratio of 1.70 and a debt-to-equity ratio of 1.03. The stock has a market cap of $959.44 million, a PE ratio of 19.75 and a beta of 0.83.

Innophos (NASDAQ:IPHS) last posted its quarterly earnings results on Tuesday, May 1st. The specialty chemicals company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.06. Innophos had a return on equity of 14.26% and a net margin of 2.95%. The business had revenue of $205.00 million for the quarter, compared to analysts’ expectations of $196.91 million. During the same quarter in the prior year, the business earned $0.59 EPS. The firm’s revenue for the quarter was up 23.5% on a year-over-year basis. equities analysts forecast that Innophos will post 2.7 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 5th. Shareholders of record on Friday, May 18th were issued a $0.48 dividend. This represents a $1.92 dividend on an annualized basis and a yield of 3.95%. The ex-dividend date of this dividend was Thursday, May 17th. Innophos’s dividend payout ratio is 78.05%.

Innophos Company Profile

Innophos Holdings, Inc, together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste.

Get a free copy of the Zacks research report on Innophos (IPHS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply